Actively Recruiting
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Led by Loyola University · Updated on 2023-03-08
100
Participants Needed
1
Research Sites
190 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.
CONDITIONS
Official Title
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Between 12 months and 36 months after allogeneic stem cell transplantation
- Donor sources include matched related, matched unrelated, or cord blood
- Diagnosed with any malignant hematological disease such as acute leukemia, myelodysplastic syndrome, non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, or myeloproliferative disorders
- Any conditioning regimen allowed
- Any planned immunosuppressive prophylactic treatment
- Patients with chronic graft-versus-host disease on stable immunosuppression
- Ability to understand and willing to sign written informed consent
- Negative pregnancy test if female of childbearing potential
You will not qualify if you...
- Had shingles after an allogeneic transplant and before enrollment
- Currently pregnant
- History of allergic reactions to Shingrix or similar compounds
- Relapse of primary hematological disease
- Previous allogeneic stem cell transplantation
- Acute disease at vaccination time
- Thrombocytopenia making intramuscular injection unsafe
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Loyola University Medical Center
Maywood, Illinois, United States, 60153
Actively Recruiting
Research Team
P
Patrick A Hagen
CONTACT
M
Mary Lee
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here